Novartis International AG CEO Net Worth

Last Updated Mar 10, 2025
CEO NameVas Narasimhan
NationalitySwitzerland
Net Worth Estimation$40 million

Vas Narasimhan, current CEO of Novartis International AG, has an estimated net worth of around $40 million due to his high executive compensation packages, stock awards, and long tenure at Novartis. Public filings and corporate disclosures attribute his wealth to annual salaries, performance bonuses, and appreciation of Novartis equity.

Vas Narasimhan's estimated net worth of 40,000,000 USD is 40% of the maximum (90,000,000 USD) and 300% of the minimum (10,000,000 USD) CEO net worth range for the healthcare sector. His net worth positions him in the upper segment of CEOs within this estimated industry bracket.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Vas Narasimhan Performance in Novartis International AG

Vas Narasimhan, CEO of Novartis International AG since 2018, is recognized for his data-driven leadership and emphasis on innovation in pharmaceuticals. He has implemented strategic decisions focused on digital transformation, cutting-edge research, and portfolio optimization, significantly enhancing Novartis' R&D productivity and pipeline strength. His impact includes driving sustainable growth, boosting shareholder value, and positioning Novartis as a leader in precision medicine and biosimilars.


Latest News

Novartis CEO Drives Major Expansion with $12B Avidity Biosciences Acquisition

Novartis CEO Vas Narasimhan leads the company's strategic push into RNA therapeutics, acquiring Avidity Biosciences for $12 billion to bolster its neuroscience pipeline and target rare neuromuscular diseases. The deal highlights Novartis' commitment to innovation and long-term growth, with expected sales growth acceleration and new first-in-class medicines in development.
Source: http://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Novartis International AG are subject to change from time to time.

Comments

No comment yet